Soroush Najdaghi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Soroush Najdaghi has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
Delaram Narimani Davani
14 shared publicationsAzam Yalameh Aliabadi
5 shared publications- Azin Alizadehasl
Cardio‐Oncology Research Center Rajaie Cardiovascular Medical and Research Institute Tehran Iran
5 shared publications Vahid Shaygannejad
Isfahan Neurosciences Research Center, Isfahan University of Medical Science, Isfahan, Iran
5 shared publicationsOmid Mirmosayyeb
Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
4 shared publicationsSeyedeh Fatemeh Hosseini Jebelli
Cardio‐Oncology Research Center Rajaie Cardiovascular Medical and Research Institute Tehran Iran
4 shared publications
Latest Publications
- Open Access
- 4 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (19) , 7692
Machine Learning for Clinical Outcome Prediction After Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis of Predictive Performance, Validation, and Clinical Readiness
Background: Machine learning (ML) models are increasingly used to predict adverse outcomes after transcatheter aortic valve replacement (TAVR), but their generalizability and clinical readiness remain uncertain. We evaluated predictive performance across post-TAVR outcomes, emphasizing validation quality, transportability, methodological bias, and clinical utility. Methods: PubMed/MEDLINE, Embase, Scopus, and Web of Science were searched from inception through 6 August 2026 for supervised ML studies reporting out-of-sample performance for clinically relevant post-TAVR outcomes. Overlapping source populations were audited before synthesis. Areas under the receiver operating characteristic curve (AUCs) were pooled on the logit scale using restricted maximum likelihood (REML) random-effects models with modified Hartung–Knapp inference and prediction intervals. Prespecified analyses examined validation maturity, predictor timing, prediction horizon, data architecture, and risk of bias. Within-study dependence was addressed using multilevel meta-regression with bias-reduced cluster-robust variance estimation (CR2); Bayesian analyses complemented the primary synthesis. Results: Sixty-seven full-text reports were included. Twenty independent source/report families contributed to mortality meta-analysis, yielding a pooled AUC of 0.791 (95% confidence interval [CI], 0.732–0.840; I2 = 91.5%; prediction interval, 0.480–0.940). The high heterogeneity and wide prediction interval indicate that this pooled AUC is an average across heterogeneous settings rather than a transportable performance guarantee. Stronger external, temporal, geographic, or inter-centre evaluation showed lower discrimination than internal/resampled evaluation (0.754 vs. 0.814; p = 0.299), while preprocedural models yielded 0.767 versus 0.866 for peri-/postprocedural or mixed models (p = 0.083). High-risk studies showed higher apparent mortality discrimination than low/unclear-risk studies (0.895 vs. 0.747; p for interaction = 0.0009); this observational comparison involved only five high-risk mortality studies and should not be interpreted causally. The Bayesian-adjusted difference was +0.118 AUC units (95% credible interval [CrI], +0.037 to +0.179). Pooled AUCs were 0.760 for permanent pacemaker implantation (PPMI), 0.778 for broader conduction abnormalities, and 0.747 for paravalvular leak (PVL). No algorithm family showed reproducible superiority (p = 0.775). Stronger independent evaluation, calibration/Brier assessment, and decision-curve analysis were reported in only 18/67, 23/67, and 10/67 reports, respectively. Conclusions: ML shows promising post-TAVR discrimination, particularly for mortality, but substantial heterogeneity, limited independent validation, and sparse calibration and decision utility assessment constrain clinical translation. A high AUC alone should not be interpreted as evidence of transportability or clinical usefulness.
- 4 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (19) , 7692
Open AccessMachine Learning for Clinical Outcome Prediction After Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis of Predictive Performance, Validation, and Clinical Readiness
Background: Machine learning (ML) models are increasingly used to predict adverse outcomes after transcatheter aortic valve replacement (TAVR), but their generalizability and clinical readiness remain uncertain. We evaluated predictive performance across post-TAVR outcomes, emphasizing validation quality, transportability, methodological bias, and clinical utility. Methods: PubMed/MEDLINE, Embase, Scopus, and Web of Science were searched from inception through 6 August 2026 for supervised ML studies reporting out-of-sample performance for clinically relevant post-TAVR outcomes. Overlapping source populations were audited before synthesis. Areas under the receiver operating characteristic curve (AUCs) were pooled on the logit scale using restricted maximum likelihood (REML) random-effects models with modified Hartung–Knapp inference and prediction intervals. Prespecified analyses examined validation maturity, predictor timing, prediction horizon, data architecture, and risk of bias. Within-study dependence was addressed using multilevel meta-regression with bias-reduced cluster-robust variance estimation (CR2); Bayesian analyses complemented the primary synthesis. Results: Sixty-seven full-text reports were included. Twenty independent source/report families contributed to mortality meta-analysis, yielding a pooled AUC of 0.791 (95% confidence interval [CI], 0.732–0.840; I2 = 91.5%; prediction interval, 0.480–0.940). The high heterogeneity and wide prediction interval indicate that this pooled AUC is an average across heterogeneous settings rather than a transportable performance guarantee. Stronger external, temporal, geographic, or inter-centre evaluation showed lower discrimination than internal/resampled evaluation (0.754 vs. 0.814; p = 0.299), while preprocedural models yielded 0.767 versus 0.866 for peri-/postprocedural or mixed models (p = 0.083). High-risk studies showed higher apparent mortality discrimination than low/unclear-risk studies (0.895 vs. 0.747; p for interaction = 0.0009); this observational comparison involved only five high-risk mortality studies and should not be interpreted causally. The Bayesian-adjusted difference was +0.118 AUC units (95% credible interval [CrI], +0.037 to +0.179). Pooled AUCs were 0.760 for permanent pacemaker implantation (PPMI), 0.778 for broader conduction abnormalities, and 0.747 for paravalvular leak (PVL). No algorithm family showed reproducible superiority (p = 0.775). Stronger independent evaluation, calibration/Brier assessment, and decision-curve analysis were reported in only 18/67, 23/67, and 10/67 reports, respectively. Conclusions: ML shows promising post-TAVR discrimination, particularly for mortality, but substantial heterogeneity, limited independent validation, and sparse calibration and decision utility assessment constrain clinical translation. A high AUC alone should not be interpreted as evidence of transportability or clinical usefulness.
- Open Access
- 23 December 2025
- Published by Elsevier in Heart Rhythm O2
- Vol. 7 (3) , 598-618
Safety and efficacy of leadless pacemakers: A systematic review and meta-analysis
- 23 December 2025
- Published by Elsevier in Heart Rhythm O2
- Vol. 7 (3) , 598-618
Open AccessSafety and efficacy of leadless pacemakers: A systematic review and meta-analysis
- Top Cited PapersOpen Access
- 1 August 2025
- Published by American Medical Association (AMA) in JAMA Neurology
- Vol. 82 (8) , 765-787
Global, Regional, and National Burden of Nontraumatic Subarachnoid Hemorrhage
Importance: Nontraumatic subarachnoid hemorrhage (SAH) represents the third most common stroke type with unique etiologies, risk factors, diagnostics, and treatments. Nevertheless, epidemiological studies often cluster SAH with other stroke types leaving its distinct burden estimates obscure. Objective: To estimate the worldwide burden of SAH. Design, Setting, and Participants: Based on the repeated cross-sectional Global Burden of Disease (GBD) 2021 study, the global burden of SAH in 1990 to 2021 was estimated. Moreover, the SAH burden was compared with other diseases, and its associations with 14 individual risk factors were investigated with available data in the GBD 2021 study. The GBD study included the burden estimates of nontraumatic SAH among all ages in 204 countries and territories between 1990 and 2021. Exposures: SAH and 14 modifiable risk factors. Main Outcomes and Measures: Absolute numbers and age-standardized rates with 95% uncertainty intervals (UIs) of SAH incidence, prevalence, mortality, and disability-adjusted life-years (DALYs) as well as risk factor–specific population attributable fractions (PAFs). Results: In 2021, the global age-standardized SAH incidence was 8.3 (95% UI, 7.3-9.5), prevalence was 92.2 (95% UI, 84.1-100.6), mortality was 4.2 (95% UI, 3.7-4.8), and DALY rate was 125.2 (95% UI, 110.5-142.6) per 100 000 people. The highest burden estimates were found in Latin America, the Caribbean, Oceania, and high-income Asia Pacific. Although the absolute number of SAH cases increased, especially in regions with a low sociodemographic index, all age-standardized burden rates decreased between 1990 and 2021: the incidence by 28.8% (95% UI, 25.7%-31.6%), prevalence by 16.1% (95% UI, 14.8%-17.7%), mortality by 56.1% (95% UI, 40.7%-64.3%), and DALY rate by 54.6% (95% UI, 42.8%-61.9%). Of 300 diseases, SAH ranked as the 36th most common cause of death and 59th most common cause of DALY in the world. Of all worldwide SAH-related DALYs, 71.6% (95% UI, 63.8%-78.6%) were associated with the 14 modeled risk factors of which high systolic blood pressure (population attributable fraction [PAF] = 51.6%; 95% UI, 38.0%-62.6%) and smoking (PAF = 14.4%; 95% UI, 12.4%-16.5%) had the highest attribution. Conclusions and Relevance: Although the global age-standardized burden rates of SAH more than halved over the last 3 decades, SAH remained one of the most common cardiovascular and neurological causes of death and disabilities in the world, with increasing absolute case numbers. These findings suggest evidence for the potential health benefits of proactive public health planning and resource allocation toward the prevention of SAH.
- 1 August 2025
- Published by American Medical Association (AMA) in JAMA Neurology
- Vol. 82 (8) , 765-787
Top Cited PapersOpen AccessGlobal, Regional, and National Burden of Nontraumatic Subarachnoid Hemorrhage
Importance: Nontraumatic subarachnoid hemorrhage (SAH) represents the third most common stroke type with unique etiologies, risk factors, diagnostics, and treatments. Nevertheless, epidemiological studies often cluster SAH with other stroke types leaving its distinct burden estimates obscure. Objective: To estimate the worldwide burden of SAH. Design, Setting, and Participants: Based on the repeated cross-sectional Global Burden of Disease (GBD) 2021 study, the global burden of SAH in 1990 to 2021 was estimated. Moreover, the SAH burden was compared with other diseases, and its associations with 14 individual risk factors were investigated with available data in the GBD 2021 study. The GBD study included the burden estimates of nontraumatic SAH among all ages in 204 countries and territories between 1990 and 2021. Exposures: SAH and 14 modifiable risk factors. Main Outcomes and Measures: Absolute numbers and age-standardized rates with 95% uncertainty intervals (UIs) of SAH incidence, prevalence, mortality, and disability-adjusted life-years (DALYs) as well as risk factor–specific population attributable fractions (PAFs). Results: In 2021, the global age-standardized SAH incidence was 8.3 (95% UI, 7.3-9.5), prevalence was 92.2 (95% UI, 84.1-100.6), mortality was 4.2 (95% UI, 3.7-4.8), and DALY rate was 125.2 (95% UI, 110.5-142.6) per 100 000 people. The highest burden estimates were found in Latin America, the Caribbean, Oceania, and high-income Asia Pacific. Although the absolute number of SAH cases increased, especially in regions with a low sociodemographic index, all age-standardized burden rates decreased between 1990 and 2021: the incidence by 28.8% (95% UI, 25.7%-31.6%), prevalence by 16.1% (95% UI, 14.8%-17.7%), mortality by 56.1% (95% UI, 40.7%-64.3%), and DALY rate by 54.6% (95% UI, 42.8%-61.9%). Of 300 diseases, SAH ranked as the 36th most common cause of death and 59th most common cause of DALY in the world. Of all worldwide SAH-related DALYs, 71.6% (95% UI, 63.8%-78.6%) were associated with the 14 modeled risk factors of which high systolic blood pressure (population attributable fraction [PAF] = 51.6%; 95% UI, 38.0%-62.6%) and smoking (PAF = 14.4%; 95% UI, 12.4%-16.5%) had the highest attribution. Conclusions and Relevance: Although the global age-standardized burden rates of SAH more than halved over the last 3 decades, SAH remained one of the most common cardiovascular and neurological causes of death and disabilities in the world, with increasing absolute case numbers. These findings suggest evidence for the potential health benefits of proactive public health planning and resource allocation toward the prevention of SAH.
- Open Access
- 1 April 2025
- Published by Maad Rayan Publishing Company in Journal Of Research In Health Sciences
- Vol. 25 (2) , e00649
Predictors of Poor Sleep Quality in Heart Failure Patients: A Cross-sectional Multivariable Analysis of Clinical, Demographic, and Psychosocial Factors
Background: Sleep quality is crucial in heart failure (HF) patients, yet its associations with clinical, demographic, and psychosocial factors remain underexplored. This study examined these relationships to identify predictors of poor sleep quality. Study Design: A cross-sectional study. Methods: This cross-sectional was conducted on 354 HF patients at Shahid Chamran Heart Hospital, Isfahan, Iran (September 2023-2024). Pittsburgh Sleep Quality Index (PSQI) and Hospital Anxiety and Depression Scale (HADS) were used to evaluate sleep quality, anxiety, and depression, respectively. Random forest (RF) modeling and ordinary least squares (OLS) regression identified predictors of poor sleep quality. Results: Poor sleep quality (PSQI>7) was observed in 18% of patients who were older (70.00±6.30, P<0.001) and had lower ejection fraction (EF) (23.75±12.79%, P<0.001). This group also had higher systolic blood pressure (BP 140.67±12.50 mmHg, P=0.014). Complex medication regimens, including angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, and diuretics, were associated with poor sleep (P<0.001). Moreover, depression (HADS-depression: 5.36±0.70, P<0.001) and anxiety (HADS-anxiety: 4.84±1.32, P<0.001) were correlated with poor sleep. The RF model had an area under the curve of 0.79, and OLS regression (R2=0.280) highlighted New York Heart Association (NYHA) class and medication type as significant predictors. Conclusion: Overall, poor sleep quality in HF patients was related to older age, reduced cardiac function, higher blood pressure (BP), complex medication regimens, and increased anxiety and depression. Accordingly, multidimensional management strategies are needed to improve sleep outcomes.
- 1 April 2025
- Published by Maad Rayan Publishing Company in Journal Of Research In Health Sciences
- Vol. 25 (2) , e00649
Open AccessPredictors of Poor Sleep Quality in Heart Failure Patients: A Cross-sectional Multivariable Analysis of Clinical, Demographic, and Psychosocial Factors
Background: Sleep quality is crucial in heart failure (HF) patients, yet its associations with clinical, demographic, and psychosocial factors remain underexplored. This study examined these relationships to identify predictors of poor sleep quality. Study Design: A cross-sectional study. Methods: This cross-sectional was conducted on 354 HF patients at Shahid Chamran Heart Hospital, Isfahan, Iran (September 2023-2024). Pittsburgh Sleep Quality Index (PSQI) and Hospital Anxiety and Depression Scale (HADS) were used to evaluate sleep quality, anxiety, and depression, respectively. Random forest (RF) modeling and ordinary least squares (OLS) regression identified predictors of poor sleep quality. Results: Poor sleep quality (PSQI>7) was observed in 18% of patients who were older (70.00±6.30, P<0.001) and had lower ejection fraction (EF) (23.75±12.79%, P<0.001). This group also had higher systolic blood pressure (BP 140.67±12.50 mmHg, P=0.014). Complex medication regimens, including angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, and diuretics, were associated with poor sleep (P<0.001). Moreover, depression (HADS-depression: 5.36±0.70, P<0.001) and anxiety (HADS-anxiety: 4.84±1.32, P<0.001) were correlated with poor sleep. The RF model had an area under the curve of 0.79, and OLS regression (R2=0.280) highlighted New York Heart Association (NYHA) class and medication type as significant predictors. Conclusion: Overall, poor sleep quality in HF patients was related to older age, reduced cardiac function, higher blood pressure (BP), complex medication regimens, and increased anxiety and depression. Accordingly, multidimensional management strategies are needed to improve sleep outcomes.
- Open Access
- 27 March 2025
- Published by Wiley in Clinical Cardiology
- Vol. 48 (4) , e70124
Predicting In‐Hospital Mortality in Patients With Acute Myocardial Infarction: A Comparison of Machine Learning Approaches
Background: Acute myocardial infarction (AMI) remains a leading global cause of mortality. This study explores predictors of in‐hospital mortality among AMI patients using advanced machine learning (ML) techniques.Methods: Data from 7422 AMI patients treated with percutaneous coronary intervention (PCI) at Tehran Heart Center (2015–2021) were analyzed. Fifty‐eight clinical, demographic, and laboratory variables were evaluated. Seven ML algorithms, including Random Forest (RF), logistic regression with LASSO, and XGBoost, were implemented. The data set was divided into training (70%) and testing (30%) subsets, with fivefold cross‐validation. The class imbalance was addressed using the synthetic minority oversampling technique (SMOTE). Model predictions were interpreted using SHapley Additive exPlanations (SHAP).Results: In‐hospital mortality occurred in 129 patients (1.74%). RF achieved the highest predictive performance, with an area under the curve (AUC) of 0.924 (95% CI 0.893–0.954), followed by XGBoost (AUC 0.905) and logistic regression with LASSO (AUC 0.893). Sensitivity analysis in STEMI patients confirmed RF's robust performance (AUC 0.900). SHAP analysis identified key predictors, including lower left ventricular ejection fraction (LVEF; 33.24% vs. 43.46% in survivors, p < 0.001), higher fasting blood glucose (190.38 vs. 132.29 mg/dL, p < 0.001), elevated serum creatinine, advanced age (70.92 vs. 61.88 years, p < 0.001), and lower LDL‐C levels. Conversely, BMI showed no significant association (p = 0.456).Conclusion: ML algorithms, particularly RF, effectively predict in‐hospital mortality in AMI patients, highlighting critical predictors such as LVEF and biochemical markers. These insights offer valuable tools for enhancing clinical decision‐making and improving patient outcomes.
- 27 March 2025
- Published by Wiley in Clinical Cardiology
- Vol. 48 (4) , e70124
Open AccessPredicting In‐Hospital Mortality in Patients With Acute Myocardial Infarction: A Comparison of Machine Learning Approaches
Background: Acute myocardial infarction (AMI) remains a leading global cause of mortality. This study explores predictors of in‐hospital mortality among AMI patients using advanced machine learning (ML) techniques.Methods: Data from 7422 AMI patients treated with percutaneous coronary intervention (PCI) at Tehran Heart Center (2015–2021) were analyzed. Fifty‐eight clinical, demographic, and laboratory variables were evaluated. Seven ML algorithms, including Random Forest (RF), logistic regression with LASSO, and XGBoost, were implemented. The data set was divided into training (70%) and testing (30%) subsets, with fivefold cross‐validation. The class imbalance was addressed using the synthetic minority oversampling technique (SMOTE). Model predictions were interpreted using SHapley Additive exPlanations (SHAP).Results: In‐hospital mortality occurred in 129 patients (1.74%). RF achieved the highest predictive performance, with an area under the curve (AUC) of 0.924 (95% CI 0.893–0.954), followed by XGBoost (AUC 0.905) and logistic regression with LASSO (AUC 0.893). Sensitivity analysis in STEMI patients confirmed RF's robust performance (AUC 0.900). SHAP analysis identified key predictors, including lower left ventricular ejection fraction (LVEF; 33.24% vs. 43.46% in survivors, p < 0.001), higher fasting blood glucose (190.38 vs. 132.29 mg/dL, p < 0.001), elevated serum creatinine, advanced age (70.92 vs. 61.88 years, p < 0.001), and lower LDL‐C levels. Conversely, BMI showed no significant association (p = 0.456).Conclusion: ML algorithms, particularly RF, effectively predict in‐hospital mortality in AMI patients, highlighting critical predictors such as LVEF and biochemical markers. These insights offer valuable tools for enhancing clinical decision‐making and improving patient outcomes.
- Open Access
- 1 March 2025
- Published by Wiley in Clinical Cardiology
- Vol. 48 (3) , e70104
Renal Denervation Effects on Blood Pressure in Resistant and Uncontrolled Hypertension: A Meta‐Analysis of Sham‐Controlled Randomized Clinical Trials
Background: Although some guidelines recommend Renal denervation (RDN) as an alternative to anti‐HTN medications, there are concerns about its efficacy and safety. We aimed to evaluate the benefits and harms of RDN in a systematic review and meta‐analysis of sham‐controlled randomized clinical trials (RCT).Methods: Databases were searched until September 10th, 2024, to identify RCTs evaluating RDN for treating URH versus sham control. The primary outcomes were the change in office and ambulatory 24‐h systolic (SBP) and diastolic blood pressure (DBP). Secondary outcomes were changes in daytime and nighttime SBP and DBP, home BP, number of anti‐HTN drugs, and related complications. Mean differences (MD) and relative risks (RR) described the effects of RDN on BP and complications, respectively, using random effects meta‐analyses. GRADE methodology was used to assess the certainty of evidence (COE).Results: We found 16 included sham‐controlled RCTs [RDN (n = 1594) vs. sham (n = 1225)]. RDN significantly reduced office SBP (MD −4.26 mmHg, 95% CI: −5.68 to −2.84), 24 h ambulatory SBP (MD −2.63 mmHg), office DBP (MD −2.15 mmHg), 24‐h ambulatory DBP (MD −1.27 mmHg), and daytime SBP and DBP (MD −3.29 and 2.97 mmHg), compared to the sham. The rate of severe complications was low in both groups (0%–2%). The heterogeneity was high among most indices, and CoE was very low for most outcomes.Conclusion: RDN significantly reduced several SBP and DBP outcomes versus sham without significantly increasing complications. This makes RDN a potentially effective alternative to medications in URH.
- 1 March 2025
- Published by Wiley in Clinical Cardiology
- Vol. 48 (3) , e70104
Open AccessRenal Denervation Effects on Blood Pressure in Resistant and Uncontrolled Hypertension: A Meta‐Analysis of Sham‐Controlled Randomized Clinical Trials
Background: Although some guidelines recommend Renal denervation (RDN) as an alternative to anti‐HTN medications, there are concerns about its efficacy and safety. We aimed to evaluate the benefits and harms of RDN in a systematic review and meta‐analysis of sham‐controlled randomized clinical trials (RCT).Methods: Databases were searched until September 10th, 2024, to identify RCTs evaluating RDN for treating URH versus sham control. The primary outcomes were the change in office and ambulatory 24‐h systolic (SBP) and diastolic blood pressure (DBP). Secondary outcomes were changes in daytime and nighttime SBP and DBP, home BP, number of anti‐HTN drugs, and related complications. Mean differences (MD) and relative risks (RR) described the effects of RDN on BP and complications, respectively, using random effects meta‐analyses. GRADE methodology was used to assess the certainty of evidence (COE).Results: We found 16 included sham‐controlled RCTs [RDN (n = 1594) vs. sham (n = 1225)]. RDN significantly reduced office SBP (MD −4.26 mmHg, 95% CI: −5.68 to −2.84), 24 h ambulatory SBP (MD −2.63 mmHg), office DBP (MD −2.15 mmHg), 24‐h ambulatory DBP (MD −1.27 mmHg), and daytime SBP and DBP (MD −3.29 and 2.97 mmHg), compared to the sham. The rate of severe complications was low in both groups (0%–2%). The heterogeneity was high among most indices, and CoE was very low for most outcomes.Conclusion: RDN significantly reduced several SBP and DBP outcomes versus sham without significantly increasing complications. This makes RDN a potentially effective alternative to medications in URH.
- Top Cited PapersOpen Access
- 5 December 2024
- Published by Elsevier in The Lancet
- Vol. 404 (10469) , 2314-2340
The burden of diseases, injuries, and risk factors by state in the USA, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
- 5 December 2024
- Published by Elsevier in The Lancet
- Vol. 404 (10469) , 2314-2340
Top Cited PapersOpen AccessThe burden of diseases, injuries, and risk factors by state in the USA, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
- Open Access
- 3 December 2024
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 44 (1) , 1-31
The Role of Extracellular Vesicles and Microparticles in Central Nervous System Disorders: Mechanisms, Biomarkers, and Therapeutic Potential
Microscopic, membranous vesicles known as extracellular vesicles (EVs) have been proposed to play a role in the mechanisms underlying central nervous system (CNS) diseases. EVs are secreted by a variety of cells, including myeloid, endothelial, microglial, oligodendroglial, and mesenchymal stem cells (MSCs). Body fluids such as plasma, urine, and cerebrospinal fluid (CSF) contain microparticles (MPs). The detection of MPs in CSF may indicate genetic or environmental susceptibility to conditions such as schizophrenia, schizoaffective disorder, and bipolar disorder. MPs of different origins can exhibit changes in specific biomarkers at various stages of the disease, aiding in the diagnosis and monitoring of neurological conditions. However, understanding the role and clinical applications of MPs is complicated by challenges such as their isolation and dual roles within the CNS. In this review, we discuss the history, characteristics, and roles of MPs in CNS diseases. We also provide practical insights for future research and highlight the challenges that obscure the therapeutic potential of MPs.
- 3 December 2024
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 44 (1) , 1-31
Open AccessThe Role of Extracellular Vesicles and Microparticles in Central Nervous System Disorders: Mechanisms, Biomarkers, and Therapeutic Potential
Microscopic, membranous vesicles known as extracellular vesicles (EVs) have been proposed to play a role in the mechanisms underlying central nervous system (CNS) diseases. EVs are secreted by a variety of cells, including myeloid, endothelial, microglial, oligodendroglial, and mesenchymal stem cells (MSCs). Body fluids such as plasma, urine, and cerebrospinal fluid (CSF) contain microparticles (MPs). The detection of MPs in CSF may indicate genetic or environmental susceptibility to conditions such as schizophrenia, schizoaffective disorder, and bipolar disorder. MPs of different origins can exhibit changes in specific biomarkers at various stages of the disease, aiding in the diagnosis and monitoring of neurological conditions. However, understanding the role and clinical applications of MPs is complicated by challenges such as their isolation and dual roles within the CNS. In this review, we discuss the history, characteristics, and roles of MPs in CNS diseases. We also provide practical insights for future research and highlight the challenges that obscure the therapeutic potential of MPs.
- Open Access
- 29 November 2024
- Published by Wiley in Clinical Case Reports
- Vol. 12 (12) , e9610
Combination Therapy of Albendazole and Praziquantel for Treatment of Cardiac and Multiorgan Hydatid Cyst: A Case Report of Novel Treatment and Literature Review
Cardiac hydatid cysts (CHC) are rare complications of echinococcosis, often presenting diagnostic and therapeutic challenges. We report a case of recurrent CHC in a 35‐year‐old male with a history of cerebral and pelvic hydatid cysts. Diagnostic imaging revealed significant cardiac involvement, necessitating surgical intervention. Postoperative management included a combination of albendazole and praziquantel, resulting in marked improvement during follow‐up. This case highlights the complexities of treating recurrent CHC and suggests that combination therapy may offer benefits in managing extensive cysts. Further research is needed to refine treatment strategies for such cases.
- 29 November 2024
- Published by Wiley in Clinical Case Reports
- Vol. 12 (12) , e9610
Open AccessCombination Therapy of Albendazole and Praziquantel for Treatment of Cardiac and Multiorgan Hydatid Cyst: A Case Report of Novel Treatment and Literature Review
Cardiac hydatid cysts (CHC) are rare complications of echinococcosis, often presenting diagnostic and therapeutic challenges. We report a case of recurrent CHC in a 35‐year‐old male with a history of cerebral and pelvic hydatid cysts. Diagnostic imaging revealed significant cardiac involvement, necessitating surgical intervention. Postoperative management included a combination of albendazole and praziquantel, resulting in marked improvement during follow‐up. This case highlights the complexities of treating recurrent CHC and suggests that combination therapy may offer benefits in managing extensive cysts. Further research is needed to refine treatment strategies for such cases.